SPARC issues warrants worth Rs 1,200 crore to promoter Dilip Shanghvi, others
New Delhi: Sun Pharma Advanced Research Company (SPARC) plans to raise up to Rs 1,200 crore by way of issuing warrants to the company''s promoter Dilip Shanghvi and other entities.
The proposal was approved by the company''s board during its meeting held on Wednesday, according to a regulatory filing.
As per the filing, the board considered and approved issuing "up to 6,74,70,203 warrants each convertible into, or exchangeable for, one equity share within the period of 18 months at a price of Rs 178 each" to Dilip Shantilal Shanghvi, promoter of the company and to certain other non-promoter group persons.
These warrants -- aggregating up to Rs 12,00,96,96,134 -- would be allotted by way of a preferential issue.
Upon issue of warrants, an amount equivalent to 25 per cent of the total issue size shall be called upfront from the proposed allottees, the filing said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.